Literature DB >> 7749594

Serotonin-degradative pathways in the toad (Bufo bufo japonicus) brain: clues to the pharmacological analysis of human psychiatric disorders.

N Takeda1.   

Abstract

Bufotenine (BUTN) is a hallucinogen with psychotropic effects. High levels of BUTN and its precursor, N-methylserotonin are shown for the first time to occur and to accumulate mainly in the brain during the degradation of serotonin in the central nervous system of the toad, Bufo bufo japonicus. These compounds are concentrated in the hindbrain, which includes the cerebellum and medulla oblongata. BUTN can also be detected in blood and urine specimens from the toad. In humans, autism is a subtype of schizophrenia that appears to be a functional disease of the brain. BUTN can be detected in urine specimens from infant autistic patients. Analysis by three-dimensional HPLC suggests that the presence and levels of BUTN may be important markers for the diagnosis of autism. It appears, therefore, that some aspects of the central nervous system of Bufo may provide useful pharmacological clues to the etiology of human psychiatric diseases, such as autism, that are known to be linked to the methylation of serotonin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7749594     DOI: 10.1016/1367-8280(94)90051-5

Source DB:  PubMed          Journal:  Comp Biochem Physiol Pharmacol Toxicol Endocrinol


  4 in total

1.  Microbial liberation of N-methylserotonin from orange fiber in gnotobiotic mice and humans.

Authors:  Nathan D Han; Jiye Cheng; Omar Delannoy-Bruno; Daniel Webber; Nicolas Terrapon; Bernard Henrissat; Dmitry A Rodionov; Aleksandr A Arzamasov; Andrei L Osterman; David K Hayashi; Alexandra Meynier; Sophie Vinoy; Chandani Desai; Stacey Marion; Michael J Barratt; Andrew C Heath; Jeffrey I Gordon
Journal:  Cell       Date:  2022-06-27       Impact factor: 66.850

2.  Opioid use affects antioxidant activity and purine metabolism: preliminary results.

Authors:  Paolo Mannelli; Ashwin Patkar; Steve Rozen; Wayne Matson; Ranga Krishnan; Rima Kaddurah-Daouk
Journal:  Hum Psychopharmacol       Date:  2009-12       Impact factor: 1.672

Review 3.  Mass spectrometry as a tool for studying autism spectrum disorder.

Authors:  Alisa G Woods; Armand G Ngounou Wetie; Izabela Sokolowska; Stefanie Russell; Jeanne P Ryan; Tanja Maria Michel; Johannes Thome; Costel C Darie
Journal:  J Mol Psychiatry       Date:  2013-05-21

4.  Opportunities in Novel Psychotropic Drug Design from Natural Compounds.

Authors:  Siu Wa Tang; Wayne H Tang
Journal:  Int J Neuropsychopharmacol       Date:  2019-09-01       Impact factor: 5.176

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.